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Abstract

Background: Hereditary Fructose Intolerance (HFI) is an inborn error of metabolism which
results in the absence of an effective Aldolase B enzyme. Without this enzyme, ingestion of
fructose and metabolic precursors leads to acute illness, multiorgan damage, and possible death.
The increased presence of these sugars results in earlier onset of symptoms and more difficulty
for those with HFI.
Purpose: The project’s aim is to increase awareness of HFI in healthcare providers using a
learning module and assessments of knowledge at three different points in time.
Methods: The IOWA model for evidence-based practice projects was applied during the
development and completion of this project. A learning module was used, and knowledge was
assessed before, after, and one month after following completion of the module.
Results: Self-reported awareness of HFI increased on a 4-point Likert Scale from 1.6 to 3.06
from preassessment to post-assessment and from 1.5 to 2.8 for awareness of FM. The average
amount of symptoms identified as being related to HFI increased from 1.95 to 3.76
(preassessment and post-assessment). Choice of genetic testing increased from 31.3% of
participants to 90% in the post-assessment. The selection of dangerous diagnostic tests (IV
fructose challenge and hydrogen breath test) decreased from preassessment (24.4% and 35.6%)
to post-assessment (23.3% and 16.7%).
Discussion: Education focused on HFI had a significant impact on participants’ knowledge base
as seen by the pre and post-test responses. As this project was conducted during the COVID-19
pandemic, significant attrition from the post-evaluation to the follow-up assessment was seen.
Therefore, it is unclear whether the knowledge would be sustained over time. Future reiterations
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of this project should consider the requirements of all completion of the module within a
specified timeframe and should include follow-up post-assessment items.

Keywords: Hereditary Fructose Intolerance, Aldolase B, Fructose Intolerance, Inborn Errors of
Metabolism
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Chapter 1: Problem Identification, Clinical Question, and Evidence Review
Background and Introduction to the Problem
Inborn errors of metabolism are rare individually, but overall, occur once in every 1,500
to 5,000 births (Pourfarzam & Zadhoush, 2013). The early screening and diagnosis of genetic
mutations in newborns can lead to earlier identification and intervention. This often will
significantly impact the health and well-being of the infant, allowing for current best practices to
guide patient care. While many disorders are screened for during elective carrier screenings and
on “Baby’s First Test” newborn screening, the autonomy in a parent’s decision to undergo a
carrier screening and the absence of many genetic disorders during the newborn screenings can
result in children going undiagnosed (Baby’s First Test, 2018).
Presentation of these autosomal recessive metabolic disorders is often challenging to
identify and differentiate from other disease processes. The cause of this is twofold. First, it is
due to the rarity of individual disorders. Second, the presentation of patients with metabolic
disorders varies greatly. The patient presentation will vary based on factors, including the gene
impacted by the mutation, the type of mutation that occurred, and the effect on the individual.
Inborn errors of metabolism can affect any metabolic pathway in the body.
Increased awareness of these disorders will likely result in earlier diagnosis and
appropriate interventions. It is more likely that practitioners can help patients with these
disorders avoid acute illness and avoid long complications and damages based on their specific
error of metabolism through early diagnosis and recommendation of appropriate interventions.
Description of Problem: Need for Awareness of Hereditary Fructose Intolerance (HFI)
Incredible progress in genetic testing and newborn screenings is evident in the successful
early identification of patients with Phenylketonuria (PKU) (Bosch et al., 2105). Phenylketonuria
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(PKU) is an inborn error of metabolism resulting in decreased metabolism of the amino acid
phenylalanine. If PKU is left untreated, intellectual disability, seizures, behavioral problems,
and mental disorders result. Hereditary fructose intolerance (HFI) also occurs from an inborn
error of metabolism caused by the absence of an enzyme called aldolase B. In people with HFI,
ingestion of fructose (fruit sugar) and sucrose (cane or beet sugar, table sugar) causes severe
hypoglycemia (low blood sugar), a build-up of substances in the liver, and can result in death.
While both HFI and PKU are autosomal recessive metabolic disorders, both are treated
by avoiding substances that rely on a certain enzyme for metabolism. In PKU, a deficiency in
phenylalanine hydroxylase inhibits the metabolism of the amino acid phenylalanine (Foreman et
al., 2021). In HFI, the genetic mutation results in either the absence of or the production of
ineffective aldolase B enzyme, which is necessary for the metabolism of fructose and the
metabolic precursors. In both disorders, complications can be avoided with early diagnosis,
family and patient education, and strict adherence to diets avoiding phenylalanine and fructose,
respectively. Unlike PKU, which is found in newborn genetic screening, HFI is often not
diagnosed until a patient is experiencing possibly life-threatening complications that could have
been avoided (Aldámiz-Echevarría et al., 2019; Bosch et al., 2015; Cox, 1993; Steinmann et al.,
2006).
Until HFI is screened more universally, it is necessary to increase awareness among
healthcare providers for many reasons discussed further in this chapter. This project aims to
increase the awareness of Hereditary Fructose Intolerance (HFI) among current and future
healthcare providers.
Confusion Between Hereditary Fructose Intolerance and Fructose Malabsorption
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Healthcare providers need increased knowledge about HFI and the difference between
HFI and fructose malabsorption (FM). Anecdotal evidence is often noted through online medical
advice columns where providers, including physicians, confuse HFI and fructose malabsorption,
which can be fatal. For instance, one said medical advice column notes a health care provider is
giving “advice” on HFI, noting that HFI is serious in children but not adults. Additionally,
inappropriate dietary interventions were recommended that may be appropriate for an FM
diagnosis but deadly for an individual with HFI. While a subject matter expert caught this error
and issued a redaction, readers had already absorbed this information. Unfortunately, this is
common in online forums, where HFI patients sometimes go for medical information. This
confusion between HFI and FM is one example of the lack of awareness and confusion between
the two pathologies (Roach, 2019a; Roach, 2019b). Confusing the diagnoses is extremely
dangerous for HFI patients and is a documented occurrence in the peer-reviewed literature.
(Gaughan et al., 2015; Usai, 2014). Furthermore, testing, and dietary recommendations for
patients with FM can be hazardous and create mortalities for those with HFI. See Appendix A
for the differences between FM and HFI.
Dietary Changes in Western Society
The increased number of sugars in our foods and drinks, especially in western societies,
puts individuals with HFI at greater risk for mortality and morbidity (Ali et al., 1998). The
consumption of high fructose corn syrup in foods and beverages has increased by more than
100% between 1970 and 1990 (Akram & Hamid, 2012). The increased presence of various
sugars in foods and beverages is linked to the increase in the number of patients identified as
having HFI due to difficulty avoiding the dangerous sugars (Akram & Hamid, 2012; Ali et al.,
1998; Cox, 1991).
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The presence of sugars in food is a potential danger anyone with HFI. The most notable
and dangerous example is the inclusion of fructose and other sugars in infant formula—many
examples of infants presenting with significant hepatic and renal damage. In the past, the initial
presentation of HFI was children with gastrointestinal complaints accompanied by a distaste for
sweets when fruit was first introduced. However, now that sugar has been added to formula, this
led to the initial production of a much younger patient with more severe complications (Li et al.,
2018).
Dangers Related to Routine and Diagnostic Medical Care
Undiagnosed patients as well as individuals with HFI but unable to communicate such as
infants, are susceptible to the dangers associated with the medical care they may receive. Routine
medical procedures can be dangerous, if not deadly, for patients of any age who have HFI. This
is due partially to the lack of knowledge about HFI by healthcare providers as well as the lack of
understanding of the severity of HFI if sugars are not entirely avoided (Ali & Cox, 1995; Ali,
Rellos, & Cox, 1998; Cox, 1993; Cox, 1995; Gaughan et al., 2015).
Of further concern are individuals with undiagnosed HFI being admitted to hospitals. For
patients with HFI, routine medical procedures can be dangerous if not deadly. This is due
possibly due to the lack of knowledge about HFI in providers or a lack of understanding or
appreciation of the severity of the metabolic disorder. Patients have died or have been
significantly harmed, such as developing hepatorenal failure, from medications, parenteral fluids,
diagnostic testing, or other treatments performed as part of diagnostics performed with
undiagnosed HFI presentations (Ali & Cox, 1995; Cox, 1993; Cox, 1995).
Infants presenting with complications from undiagnosed HFI can also be at risk during
their hospitalization using the primary method for pain management (Gaughan et al., 2015;
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Lefrak et al., 2006). This is a solution of sucrose and water, commonly known as “sweet-ease,”
which is put in the baby’s mouth with a gloved finger or on a pacifier and used as an analgesic
(Gaughan et al., 2015; Lefrak et al., 2006). Although some hospital policies list fructose
intolerance as a contraindication to use, there is no information guiding clinicians and nurses in
how to identify a patient with HFI (Melbourne, 2019). Without prompt identification of this
disorder and exclusion of offending sugars, these infants are essentially being poisoned with
sugar that their bodies are unable to digest, putting them at risk for further mortality during
hospital diagnostic procedures using this method (Gaughan et al., 2015; Li et al., 2018).
In patients of any age, routine medical care can result in death or multiorgan failure as
well. For example, the presence of sugars in medication formulations can be poisonous to
individuals with HFI due to the inability to break down these sugars. Inactive ingredients and
buffers to stabilize medications are not commonly found in food and drinks but can be added to
medication formulations, causing additional risk for these individuals (Ali & Cox, 1995; Ali et
al., 1998; Arthur & Burgess, 2017; Gaughan et al., 2015; Brooks & Tolan, 1993; Cox, 1993).
Early diagnosis and appropriate patient education emphasizing the importance of strict
adherence to a diet that avoids fructose, sucrose, sorbitol, and other precursors of fructose can
result in an individual leading a life free of complications or acute illness related to HFI
(Aldámiz-Echevarría et al., 2019; Ali & Cox, 1995; Ali et al., 1998; Cox, 1993; James et al.,
1996). Furthermore, early diagnosis and intervention can save a patient from illness, multi-organ
damage, and unnecessary suffering. However, healthcare providers need to be able to recognize
and diagnosis HFI, including understanding the differences between HFI and FM. This scholarly
project will aim to increase awareness and education on HFI and FM diagnoses and differences,
therefore, decreasing the time to identification, diagnosis, and intervention for HFI patients.
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Chapter 2: Development of Clinical Question and Evidence Review
Question Leading Project
In current and future healthcare providers (P), will a learning module about Hereditary
Fructose Intolerance (I) increase knowledge about HFI (C) compared to baseline knowledge (O)?
Evidence Search
External Evidence
A review of the available research literature on HFI was completed. This was two-fold:
to ensure that the learning module reflects the most recent research available and provide a
critical appraisal of the available literature on HFI. Search terms included “Hereditary Fructose
Intolerance,” “Fructose Intolerance,” and “Aldolase B Deficiency.” Any material that was not
relevant or was consistent with the diagnosis of Fructose Malabsorption was not included in
analysis.
Internal Evidence
Sacred Heart University’s APRN program has a comprehensive curriculum extensively
covering diverse topics necessary for future practitioners to be well-rounded and knowledgeable.
Currently the curriculum includes general knowledge of chromosomal disorders and inheritance
patterns during the program. While there is mention of some genetic disorders throughout the
program, these do not include HFI or FM. On further review of the textbooks utilized in the
program through 2018-2022, HFI is only mentioned once in a chart of metabolic disorders
without any associated discussion of symptoms, interventions, or diagnostic testing methods.
Finally, when asking APRN faculty about HFI and FM, many admitted that they themselves
were not aware of the differentiation between these disorders as well as the potential fatality with
HFI being missed. Additionally, the state of Connecticut does not require HFI as part of the
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regular newborn screening panel and providers may not be aware of the potential differences
between PKU and HFI.
Review of the Literature and Practice Guideline Evidence
While there were several articles and case studies that discuss HFI, there was no literature
found addressing the knowledge gap among providers, the frequency of misdiagnosis, the
average age of diagnosis, or the cost of misdiagnosis. Available HFI literature included topics
such as the associated genetic mutations, the pathophysiology, the clinical presentation, and
individual case studies. Additionally, there are no guidelines discussing the best practice in
diagnosing and treating individuals with HFI. Articles were evaluated and compared for
information consistency. See Appendix B, C and D for critical appraisal of the literature and a
synthesis of the results.
After reviewing many articles focusing on HFI, it was apparent that there was agreement
regarding many aspects of the pathophysiology, necessary intervention, appropriate methods of
testing of HFI. There was not, however, any practice guidelines appropriate for the treatment of
an individual with or who is believed to have HFI. While research frequently discussed the
danger of not adhering to a strict diet avoiding HFI, there are no recommendations to aid
clinicians to manage these patients.
Evidence Appraisal and Recommendations
Articles found using the search terms listed previously were focused on for analysis and
comparison. Through the analysis of multiple resources, there were many consistencies noted in
the data and recommendations. In all articles analyzed, there was consistency in the cause, signs,
and symptoms although some articles went into greater depth than others. The prevalence of HFI
differed between different sources and ranged between 1:18,000 to 1:31,000 and variations were
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noted to be due to geography (Steinmann et al., 2006; Aldámiz-Echevarría et al., 2019; Ali &
Cox, 1995; Gaghan et al., 2015; Ali et al., 1994; James et al., 1996). Other similarities within the
research included the signs and symptoms consistently seen in HFI including failure to thrive
Also of note, the research is largely focused on Caucasian populations of European
descent. Lazarin et al., (2013) discusses those carriers of HFI occurring as frequently as 1:90 in
their study but 1:81 in research. This finding contrasted with the frequency of 1:226 in African
Americans and 1:97 Middle Eastern individual. These frequencies, unlike the Caucasian
frequency, has not additional research to compare this finding to. There is a significant gap in
research looking at the frequency of HFI in minority populations. Multiple studies state that the
genetic mutation causing HFI varies within different ethnicities and geographical area therefore
the lack of data regarding HFI in minority populations may be dangerous to these individuals. In
studies of carrier screenings, HFI has been found in Northwestern European and African
American to be among the top ten most frequently occurring heterozygous genetic mutation (Ali
et al., 1998; Lazarin et al., 2013).
Through the literature review, patterns emerged regarding the presentation of patients
with HFI. The most frequently mentioned included:
•

Distaste or aversion to sweet tastes (Ali & Cox, 1995; Ali, Rellos, & Cox, 1998;
Ali, Rosien & Cox, 1992; Ali, Tuncman et al., 1994; Brooks & Tolan, 1993; Cox,
1991; Cox, 1990a; Cox, 1990b; Cox, 1993; Cross & Cox, 1990; Gaughan et al.,
2015; James et al., 1996; Kim et al., 2020; Kim et al., 2021; Li et al., 2018; Mock
et al., 1983; Steinmann & van den Berghe, 2006).

•

Postprandial hypoglycemia (Akram & Hamid, 2013; Aldámiz-Echevarría et al.,
2019; Ali & Cox, 1995; Ali, Rellos, & Cox, 1998; Ali, Rosien & Cox, 1992; Ali,
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Tuncman et al., 1994; Brooks & Tolan, 1993; Cox, 1991; Cox, 1990a; Cox,
1990b; Cox, 1993; Cross & Cox, 1990; Gaughan et al., 2015; James et al., 1996;
Kim et al., 2020; Kim et al., 2021; Li et al., 2018; Mock et al., 1983; Steinmann &
van den Berghe, 2006).
•

Failure to thrive or growth retardation (Aldámiz-Echevarría et al., 2019; Ali &
Cox, 1995; Ali et al., 1998; Ali et al., , 1992; Ali et al., 1994; Brooks & Tolan,
1993; Cox, 1991; Cox, 1990a; Cox, 1990b; Cox, 1993; Cross & Cox, 1990;
Gaughan et al., 2015; James et al., 1996; Kim et al., 2020; Kim et al., 2021; Li et
al., 2018; Mock et al., 1983; Steinmann & van den Berghe, 2006).

•

Abdominal complaints such as nausea, vomiting and abdominal pain (Akram &
Hamid, 2013; Aldámiz-Echevarría et al., 2019; Ali & Cox, 1995; Ali et al., 1998;
Ali et al., 1992; Ali et al., 1994; Brooks & Tolan, 1993; Cox, 1991; Cox, 1990a;
Cox, 1990b; Cox, 1993; Cross & Cox, 1990; Gaughan et al., 2015; James et al.,
1996; Kim et al., 2020; Kim et al., 2021; Li et al., 2018; Mock et al., 1983;
Steinmann & van den Berghe, 2006).

These symptoms that are frequently reported in patients with undiagnosed HFI or those who are
not adherent to an appropriate diet avoiding fructose and its precursors. Of these symptoms, the
aversion to sweets has been discussed as indicator to consider HFI regardless of the presence of
other symptoms (Kim et al., 2020).
Research also varies in the recommendations regarding diagnostic methodologies.
Articles published prior to 1990 recommended the use of an intravenous fructose challenge in a
controlled setting for the diagnosis of HFI (Cox, 1990a; Cox, 1990b; Cross & Cox, 1990; Mock
et al., 1983). Research after this point stated that intravenous fructose challenges were dangerous
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and should not be used for diagnosis (Ali & Cox, 1995; Ali et al., 1998; Ali et al., 1992; Ali et
al., 1994; Brooks & Tolan, 1993; Cox, 1993; Gaughan et al., 2015; James et al., 1996; Kim et al.,
2021; Steinmann & van den Berghe, 2006).
Most recently, the recommended diagnostic method is diagnostic testing for a mutation in
the gene responsible for Aldolase B production (Aldámiz-Echevarría et al., 2019; Ali et al.,
1998; Ali et al., 1992; Ali, Tuncman et al., 1994; Brooks & Tolan, 1993; Cox, 1991; Cox, 1990a;
Cox, 1990b; Cox, 1993; Gaughan et al., 2015; James et al., 1996; Kim et al., 2020; Kim et al.,
2021; Li et al., 2018; Mock et al., 1983; Steinmann & van den Berghe, 2006). Many of these
sources also introduce liver biopsy to assess Aldolase B activity as less ideal due to the
associated risks but able to confirm a diagnosis of HFI (Ali et al., 1998; Ali at al., 1992; Ali et
al., 1994; Brooks & Tolan, 1993; Cox, 1990b; Cox, 1993; Gaughan et al., 2015; James et al.,
1996; Kim et al., 2021; Steinmann & van den Berghe, 2006). Further, use of a Hydrogen Breath
test indicated for diagnosis of FM is contraindicated in HFI as all these sources state that the
most important intervention in HFI is the minimization or avoidance of fructose and its
precursors (Akram & Hamid, 2013; Aldámiz-Echevarría et al., 2019; Ali et al., 1998; Ali at al.,
1992; Ali et al., 1994; Brooks & Tolan, 1993; Cox, 1991; Cox, 1990a; Cox, 1990b; Cox, 1993;
Cross & Cox, 1990; Gaughan et al., 2015; James et al., 1996; Kim et al., 2020; Kim et al., 2021;
Li et al., 2018; Mock et al., 1983; Steinmann & van den Berghe, 2006). Analysis of the research
in regards to the symptoms and diagnostic methods discussed can be seen in Appendix E.
More recent research has been looking at the use of Carbohydrate- Deficient Transferrin
levels as an indicator of undiagnosed HFI or nonadherence with dietary restrictions (AldámizEchevarría et al., 2019; Cano et al., 2022; DiDato et al., 2019; Gaughan et al., 2015; Pronicka et
al., 2007). This finding could serve as a helpful addition to confirm diagnosis in patients who
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may not have a previously identified pathogenic mutation which it believed to lead to inability to
diagnose some individuals using genetic testing (Ali et al., 1998; Ali at al., 1992; Ali et al., 1994;
Brooks & Tolan, 1993; Gaughan et al., 2015).
Within the research, there are two sources that serve as clinical guidelines for patients
and providers but there is no single source that includes a comprehensive review of all the data
(Ali, Rellos & Cox, 1998; Gaughan et al., 2015). These clinical guidelines are thorough but there
is a need for more straight forward recommendations for the care and management of patients
with HFI about normal management and dietary recommendations.
Summary
As demonstrated in Appendices B, C, and D a synthesis of available literature was
conducted and summarized for this project. The evidence reviewed for this project revealed two
key components. 1) While there are various pieces of research discussing HFI, there is no
exhaustive review of the disease process. 2) Also, in the studies reviewed, there were no clinical
guidelines available to guide best practices for the care of patients with HFI. These findings
illuminate a gap in current research that must be addressed in the future. This scholarly project
focused on providing the most up to date knowledge base of HFI for current and future health
care providers, attending Sacred Heart University’s advanced practice provider programs. Future
recommendations will be summarized at the conclusion of this work.
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Chapter 3: Project Plans and Methods
Introduction
This evidence-based practice project was developed to increase awareness of HFI. While
the goal was to increase awareness in healthcare providers for this project, increasing awareness
can continue indefinitely through the creation of an easily accessible educational module within
a website focused on HFI. While the author ‘s immediate goal is to increase awareness to HFI,
the long-term goal is to sustain the knowledge and continue to spread awareness.
To simplify completion of the components of this project and for the long-term
sustainment of this project, a website was created through using Wix. This website is home to the
learning module and assessments for the convenience of participants. In addition, the website
contains data about HFI. Screenshots of the website and the contents within it can be seen in
Appendix F and G. This website will remain active and will reflect the questions and concerns
commonly heard within the HFI community.
This project was launched during the advent of COVID-19, therefore a virtual, online
setting for this education was modified and a targeted population to pilot the educational module
within an online environment. This format for the project provided simplicity of completion as
all components of the project. This format also allowed for sustainment of the project for future
use and a resource for individuals who have or are curious about HFI. The project measures and
outcomes shifted to an exploration of increasing HFI awareness overall. By using this form that
work will occur continuously if the website is active.
Purpose and Global Aim
This project aimed to increase awareness and understanding of HFI in current and future
clinicians. The overall goal of this project is to: 1) Provide a baseline of knowledge related to
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HFI in current and future health care providers; 2) Identify a potential gap in the curriculum for
APRN and PA students with recommendations on HFI diagnosis inclusion for program directors;
and 3) Increase awareness of HFI, patient presentation, and diagnostic methods.
Specific Aims
The global aim for this scholarly project was to increase awareness of HFI with health
care providers, specifically those who diagnose and treat patients such as APRNs, PAs, and
physicians. By providing increased awareness and education for health care providers, this will
additionally help identify and provide more rapid intervention for patients with undiagnosed
HFI. Additional specific aims of this project include: 1) education on the differences between
HRI and FM; 2) increase the knowledge of appropriate diagnostic testing in HFI patients; 3)
increase the ability to recognize HFI as a genetic inborn error metabolic disorder with students
currently enrolled at Sacred Heart University.
Framework
The Iowa Model
The IOWA Model for evidence-based practice improvement was utilized for the overall
development of this project plan (Cullen et al., 2018). This model consists of twelve steps as
seen in Appendix H. Each step included actions while allowed foe the completion of the next
step. Individual steps will be discussed in the following sections.
Identify Triggering Issues/ Opportunities
The need for increased awareness of HFI was identified as an issue. As discussed
previously, the risk of misdiagnosis and lack of diagnosis is dangerous, and potentially fatal.
Factors such as the increased use of high fructose corn syrup in foods, beverages and infant
formulas emphasized the need for increased awareness in healthcare providers (Li et al., 2019).
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This in conjunction with the absence of education on this topic in the APRN curriculum at SHU,
an opportunity was found with a goal of increasing awareness in future healthcare providers.
State the Question or Purpose
In current and future healthcare providers (P), will a learning module about Hereditary
Fructose Intolerance (I) increase knowledge about HFI (C) compared to baseline knowledge (O)?
Is This Topic a Priority?
This topic is a priority. This is due to the increased risks associated with having HFI
without an increase in awareness of the disorder and the potential for a life free of symptoms of
complications. The increased awareness, diagnosis, and introduction of appropriate interventions
are crucial for patients.
Form a Team
Completion of this project was done with a great deal of assistance from the faculty at
Sacred Heart University’s DNP-FNP program. Dr. Anna Goddard served as a mentor in the
completion of this project.
Assemble, Appraise, Synthesis Body of Evidence and Is There Sufficient Evidence
Evidence review and related discussion can be seen within the section entitled ‘Evidence
Search.’
Design and Pilot the Practice Change
The design of this project included the development of a website, learning module, and
three learning assessments. The rationale for the creation of a website was for the convenience of
participants as well as to serve as a resource for future use by practitioners and patients.
Is Change Appropriate for Adoption in Practice?
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A gap in the curriculum highlighted a need for the adoption of this project at SHU. Based
on this finding it was believed that there may be a similar gap in other educational programs for
clinicians from various background's pursuing different degrees.
Integrate, Sustain the Practice Change
Integration, sustainment, and dissemination of this project will be discussed in detail in
following sections. Integration will include sharing the address of the website that includes the
learning module and assessments. Completion will be done at the participant’s convenience.
Responses to the survey will be the sections will be done automatically using Google forms.
Sustainment of knowledge was assessed by the follow-up assessment. Also, sustainment will be
possible by maintaining the website, learning modules and assessments for future use.
Disseminate Results
The dissemination plan for this project will involve sharing the results in a poster
presentation at Sacred Heart and at upcoming conferences. Also, findings related to this project
will be submitted as an abstract or for presentation at upcoming conferences. Dissemination will
be discussed in further detail in the relevant section.
Design
The initial setup of this project included the development of a website
(http://aldolasebhfi.com). This website has information about HFI from the articles reviewed
during this project. It also includes separate links to the assessments and learning modules. A
screenshot of this website can be seen in Appendix F. By putting all items on a single website,
participants were quickly able to find the components of the project. The project was developed
and intended for participants to complete a preassessment, a learning module, a post-assessment,
and a follow-up assessment at least one month after completing the initial portion.
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Sample
Originally, practicing health care providers were targeted as participants by mailing
introductory letters of interest in the mail and as PDF documents to practice emails. This
occurred in the Fall of 2020 and this initial letter can be seen in Appendix I.
However, as indicated in the project deviation section, this project shifted to pilot the
educational module website to Sacred Heart University APRN and PA students. The SHU APRN
and PA program directors were contacted in the Fall of 2020 with an introductory letter to the
project (Appendix J). With the aid and support of the APRN faculty, Carrie Sauer, a program
administrator at Sacred Heart University, sent an email to the members of the APRN program
periodically between January 2022 and February 2022 to encourage student and faculty
participation. These emails were sent to the current students in the hybrid APRN-DNP program
between January 4th 2022, and February 3rd 2022. These emails were sent to 102 individuals on
three different occasions during that time span.
Setting
Due to the convenience of participants for completion and the increased ability to allow
for future use of this project, the setting was decided to be a virtual/online format. This decision
to be virtual was further reinforced by the fact that implementation of this project was during the
height of the COVID-19 pandemic. All components of this project can be found at
https://www.aldolasebhfi.com.
Project Team Members and Key Stakeholders
The key stakeholders for this project included the patients with potential HFI diagnoses.
However, this project aimed at increasing awareness in practicing and future providers in order
to by-proxy reach pediatric patients who may be presenting with these symptoms in the
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community currently and in the future. The DNP project director and DNP student led the
creation and implementation of this project. Other project team members included Anna
Goddard, Ph.D., APRN, CPNP-PC, fulfilled the role of DNP Project Faculty Advisor. She served
an integral part in developing the project and supplying guidance throughout the process. Susan
DeNisco DNP, APRN, FNP-BC, FAANP served as the practice mentor as the FNP-DNP director
and provided additional advice, expertise, and encouragement throughout the project,
particularly in deviations of the original aims pre-COVID-19.
Data Collection
Project Measures
The specific aims of this project include: 1) education on the differences between HFI
and FM; 2) increase the knowledge of appropriate diagnostic testing in HFI patients; 3) increase
the ability to recognize HFI as a genetic inborn error metabolic disorder with students currently
enrolled at Sacred Heart University. Therefore, the key project measures included data related to
education on HFI and FM from a pre-post evaluation survey. Demographic questions were
additionally collected.
Data Collection Plan
The project included three separate assessments for data collection throughout the
educational module. The assessments including a pre-assessment prior to taking the HFI
educational module (for baseline data on knowledge related to HFI), an immediate postassessment prior to finishing the HFI educational module, and a 1-month follow-up for the
educational module to assess knowledge sustainment.
The data collected for these assessments are Google Forms which are embedded into the
website. Google Forms were chosen for use in this project due to their ability to collect data and
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transform the data into a spreadsheet for analysis. Each assessment contains the same
knowledge-based questions except for the preassessment which had additional items related to
participant demographics. Individuals were assigned participant numbers to assess for
completion of various portions of the project in a separate document.
Data collection aimed at participant answers to knowledge-based questions surrounding
HFI at three different points in time. The preassessment data would reflect individual baseline
knowledge. The post learning module responses would reflect the knowledge gained from the
learning module. The follow-up assessment would determine whether the knowledge gained
from this project was retained. The assessments after the learning module attempted to assess for
an increase the practitioners’ awareness of HFI both short term and long term. The data
collection assessments can be seen in Appendices J, K and L.
Demographic questions addressed the frequency with which individuals from various
groups (current clinical, APRN students, and PA students) completed the project and their levels
of experience in clinical practice. A screenshot of this section can be found in Appendix K and
are listed individually below. These questions will be answered on a nominal and ordinal scale.
The questions asked in assessments attempted to address the following questions to
determine the impact of the learning module on the participant’s knowledge of HFI. Participants
are asked to report their familiarity with HFI at three different points in time to determine the
impact of the learning module on their self-reported familiarity in a 4-point Likert scale from
“no, not at all; I am not sure; Yes, somewhat familiar; Yes, very familiar.” Participants were then
asked, “What symptoms could a patient with HFI present with (Select all that apply).” To
determine how many symptoms participants, identify as occurring with HFI, a select all that
apply question was used. The choices were based on the symptoms most frequently discussed in
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the literature as discussed previously (Appendix E). Post module and follow-up assessments can
be found in Appendix L and M, respectively.
Identification of patient presentation and diagnostic test selection. This question item
was meant to look at the choice of diagnostic test selection by the participant when presented
with a patient with possible HFI. The question assessed how often participants selected the safest
and most appropriate diagnostic testing methods before and after the learning module (genetic
testing), and diagnostic testing that would confirm a diagnosis of HFI (liver biopsy for Aldolase
B activity). This item also assessed the frequency participants selected dangerous diagnostic
testing methods before and after the learning module (intravenous fructose challenge and
hydrogen breath test). Answer options in this question also included neutral options which would
not be diagnostic or detrimental (Hemoglobin A1C and Endoscopy).
Demographics
Before reading the learning module, participants were asked to complete a preassessment to
collect demographic information and assess their baseline knowledge of HFI. The appearance of
the demographic questions can be seen in Figure 1. The questions asked to participants included:
1. What is your email address?
2. What is your current discipline? (Medical Doctor, Doctor of Osteopathic Medicine,
Practicing PA, Practicing APRN or NP, PA student, APRN or NP student, other)
3. Number of years of experience in advanced clinical practice (not including time in
school). (Current student, less than one year, 1-5 years, 6-10 years, more significant
than ten years)
4. Do you have healthcare experience before practicing as a physician or in other
advanced practice roles? Select all that apply. (No different healthcare experience,
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Certified Nurse Assistant, Medical Assistant, Licensed Practical Nurse, Emergency
Responder (Emergency Medical Technician/ Paramedic), Registered Nurse, or Other).
5. If you had prior healthcare-based experience, how many years of experience do you
have? (Current student/ no other healthcare experience, less than one year, 1-5 years, 610 years, more significant than ten years)
6. What was your specialty/focus in your past healthcare experience (i.e., emergency
medicine, pediatrics, long-term care, etc.) (open-ended question)?
7. *Sacred Heart Students Only* Please select your program (Physician Assistant
Program- year 1, full time, Physician Assistant Program- year 1, part-time, Physician
Assistant Program- year 2, full time, Physician Assistant Program- year 2, part-time,
APRN Program- year 1, full time, APRN Program- year 1, part-time, APRN Programyear 2, full time, APRN Program- year 2, part-time, APRN Program- year 3, full time,
APRN Program- year 3, part-time, Unsure, PA program, Unsure APRN program).
Figure 1
Demographics Section of Preassessment

(https://www.aldolasebhfi.com/copy-of-increasing-awareness-of-aldol)
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Measures (Pre-assessment)
The following questions were asked following the demographic questions in the
preassessment. These four questions were also asked in the post-learning module and follow-up
assessments. The goal of the repetition of the following four questions was asked to determine
the participant’s baseline knowledge of HFI, the ability learned from the learning module, and
knowledge retention. The appearance of these questions can be seen in Figure 2. These questions
included:
1. Are you familiar with Hereditary Fructose Intolerance?
a. Yes, very familiar
b. Yes, somewhat familiar
c. I am not sure
d. No, not at all
2. Are you familiar with Fructose Malabsorption?
a. Yes, very familiar
b. Yes, somewhat familiar
c. I am not sure
d. No, not at all
3. What symptoms differentiate HFI from FM (select all that apply)
a. Nausea/vomiting
b. Postprandial hypoglycemia
c. Distaste for sweet flavors
d. Failure to thrive
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4. A patient presents, stating that they feel sick after eating sweet foods. During these
episodes, they describe symptoms including nausea, fatigue, shakiness, and
hypoglycemia. What test would you order for this patient initially? (Select all that
apply)
a. Hydrogen Breath Test
b. Liver Biopsy
c. Endoscopy
d. Genetic testing for metabolic disorder
e. Intravenous Fructose Challenge
f. Hemoglobin A1c
The first two questions assessed participants for their self-reported familiarity with HFI
and FM at three different points. Question three listed four symptoms often seen in patients
presenting with HFI (Aldámiz-Echevarría, 2019; Cox, 1993; Kim et al., 2020; Li et al., 2019).
Questions about HFI were developed based on the data found during the comprehensive review
of literature discussed previously.
Figure 2
Questions in Assessment portion of Follow-up Assessment

(https://www.aldolasebhfi.com/copy-of-increasing-awareness-of-aldol )
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Project Learning Module
A learning module was created using Microsoft PowerPoint. The PowerPoint was
transformed into a PDF document which was embedded into the website as shown in Figure 3
and 5. Topics covered in the learning module focused on the following:
•

The rationale for implementing this project

•

The cause and pathophysiology of HFI (Figure 4)

•

The biochemistry of the alteration in fructose metabolism in the absence of Aldolase B

•

Metabolic alterations and abnormal lab values seen in undiagnosed or uncontrolled HFI

•

Symptoms of HFI

•

Acute illness and effects of chronic ingestion of fructose and precursors

•

Patient presentation

•

Dietary management of patients with HFI

•

Clarification on need for caution with anything ingested by individuals with HFI (oral,
intravenous, medications etc.)

•

Screening methods for HFI

All information included in the learning module is based on the data compilation an analysis
discussed previously.
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Figure 3
First Slide of Learning Module

(https://www.aldolasebhfi.com/copy-2-of-increasing-awareness-of-aldol-1)

Figure 4
Pathophysiology Section of Learning Module

(https://www.aldolasebhfi.com/copy-2-of-increasing-awareness-of-aldol-1)
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Data Analysis Plan
Responses from each point in time would be collected and analyzed to look for changes
indicating success in increasing and sustaining awareness of HFI. Changes indicative of increase
in awareness of HFI include the following analyses:
•

Increase in number of symptoms identified as being present in patients with HFI on
sequential assessments.

•

Increase in number of participants who select genetic testing as a diagnostic test on
sequential assessments.

•

Decrease in number of participants who selected IV fructose challenge or hydrogen
breath test on sequential assessments.

Project Deviation
This project was initially intended to be implemented with two focal areas: to increase
awareness of HFI for practicing pediatric clinicians and primary care physician assistant and
family nurse practitioner graduate students. This project was prepared and conducted during the
COVID-19 pandemic and subsequent variations to the original intended practice change
intervention was made to support a 100% virtual environment. This revised plan included
outreach to outpatient medical facilities that care for pediatric patients in the Fairfield County
and New Haven County areas. Letters and email introductions were sent to practitioners to
recruit clinicians to partake in this project. A personalized letter was written and sent to local
pediatric clinicians to create buy-in and interest (Appendix H). A total of 14 letters and emails
were sent with three responses: 2 provider practices agreed to participate in the educational
module while one refused to participate. Eleven practices did not respond at all. A timeline gap
of more than two semesters (or 9 months) created lost interest in project participation by clinical
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providers, during a time of increased morbidity and case presentations during the COVID-19
pandemic. Therefore, it was decided to focus solely on the second intended setting and foci of
this project: current faculty and students at Sacred Heart University in the APRN and PA
advanced practice provider programs.
Ethical Merit and Project Approvals
This project was developed as an education-based evidence-based practice project aimed
to act to increase awareness. Using the SHU DNP checklist clarifying whether a project was
Quality Improvement or Research necessitating Institutional Review Board Approval (Foster,
2019). This worksheet can be found in Appendix N.
All responses form participants are password protected within the Google Forms
document. Participants are given a participation number to determine completion of each section
of the project was only done once. No other identifying information was collected. Based on the
content of the project, there are no foreseeable risks to the participants partaking in this project.
Implementation Timeline
The timeline for the completion of this project can be seen in Appendix O
Resources
The costs associated with the completion of this project are $779.12 between February
2020 and March 2022. These costs include the costs associated with keeping the website, domain
name, and any associated email. A breakdown of these expenses can be seen in Appendix P The
author paid these costs. Future upkeep of this website is expected to be $357.33 annually based
on the cost from previous years. Microsoft PowerPoint was used for the completion of the
learning module and Microsoft Excel for the organization and analysis of the data. A Google
Form was used for survey management and collection of responses
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Barriers and Solutions
The completion of this project was met with many barriers to implementation. First, The
COVID-19 pandemic made it challenging to discuss the implementation of this project with
providers in the community. Further, practicing providers in the community as well as students
in the DNP project were front-line staff during COVID-19 and had other clinical priorities
related to the morbidity and mortality seen in our communities across Connecticut, and therefore,
a DNP project based on genetic-knowledge base was not prioritized during these perilous times.
Also, the author’s timeline was suspended due to personal reasons. During this time, the faculty
changes within the PA program occurred, resulting in the project not being implemented in this
group. Another significant barrier to implementation was attrition. Of the participants asked to
participate, a majority did not complete all project components.
Summary
The plan for completion of this project was to distribute the website for the completion of
the preassessment. After completion, participants were to review the learning module and then
the post module assessment. Last participants were to receive an email reminding them to return
and complete the follow-up assessment one to three months after completion of the original
portions of the project.
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Chapter 4: Project Findings
Introduction
To increase awareness in providers, a learning module was created. To determine
efficacy in increasing knowledge, a preassessment, post assessment and follow-up assessment
were used. These assessments addressed the basic components necessary for the identification
and diagnosis of HFI for clinicians. The learning modules includes more in-depth information
about the pathophysiology, presentation, diagnosis, and interventions.
Results
After implementation of the HFI online module and pre and post data was collected, the
data was analyzed using Microsoft Excel. Each item response was reviewed as an average preand-post, as individual participant log ins was not conducted to assure anonymity. As expected, a
smaller sample size then expected resulted, most likely as a direct affect from COVID-19 and
extraneous priorities during this time. There as a decrease in participants from pre-assessment
(N=45) to post-assessment module (N=31). A follow-up at least 1-month post-module only had a
returning six respondents.
The invitation to participate in the educational module was emailed directly to 3 program
directors at Sacred Heart University. One of the directors agreed to introduce the project to
students resulting in 102 participants from the APRN programs at Sacred Heart University
receiving an email with an invitation to participate.
Additionally, letters were mailed to 14 local medical practices, however, while original
agreement to participate was agreed upon, these medical practices did not respond to the later
invitation.
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The total invitations for participation included verbal or electronic communication to 18
additional physicians, 26 APRNs, 7 PA students, 8 APRN students and one medical student.
Some participants shared the project to current or future medical practitioners.
Participant Demographics
Of the 177 individuals who received the invitation to participate, the pre-assessment
questionnaire was completed by 45 individuals (25.4%). Of these, 31 (68.8%) reported being
APRN students, 5 (11.1%) were PA students, and five (11.1%) reported being licensed APRNs.
The remaining two participants included a practicing PA and a Certified Nurse Midwife (0.02%).
Of the 45 participants, 40 (88.9%) reported experience in healthcare while 16 (35.6%)
reported more than 10 years, 11 (24.4%) reported 6-10 years, and 13 (28.9%) reported 1-5 years.
Before working as a healthcare provider or pursuing a degree, participants reported healthcare
experiences in roles including Registered Nurse (n=33, 73.3%), Emergency Medical Technician
or Paramedic (n=7, 15.6%), Medical Assistant (n=5, 11.1%), and Certified Nurses Aid (n=3,
0.06%), and Licensed Practical Nurse (n=2, 0.04%). Of these individuals, six (0.13%) reported
fulfilling two or more roles, and one (0.02%) said they had fulfilled three of these roles in the
past.
Sacred Heart University Students
Of the 36 students that took part in the project, 32 (88.9%) reported pursuing a degree as
an APRN or PA at Sacred Heart. Most participants within the sample of students who completed
the project reported being in year 3 in the part-time track (n=13, 36.1%). When assessing the
completion by SHU students, Table 1 illustrated the distribution of students with regards to their
program and progress in that program.
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Table 1
Progress within Sacred Heart APRN or PA Program
Progress
APRN Program- year 1, full time
APRN Program- year 1, part-time
APRN Program- year 2, full time
APRN Program, year 2, part-time
APRN Program- year 3, full time
APRN Program- year 3, part-time
APRN Program- modified schedule/unsure of
the progress
PA Program- year 1
PA Program- year 2
Total

Total Participants
(n)
2
0
3
2
3
13
4

Percentage

0
5
32

0%
15.62%
100%

6.25%
0%
9.38%
6.25%
9.38%
40.62%
12.5%

Familiarity with Hereditary Fructose Intolerance and Fructose Malabsorption.
The participants were asked to report their familiarity with HFI and FM before the learning
module. Responses included “Yes, very familiar,” “Yes, somewhat familiar,” “I am not sure,”
and “No, not at all.” Table 2 illustrates the frequency participants selected each response in each
assessment, with the associated percentage due to the variation in sample size. By assigning the
answer choices with the numbers based on their ordinal level (1=No, not at all; 2= I am not sure;
3= Yes, somewhat familiar; 4= Yes, very familiar) the mean response of all participants can be
calculated. The preassessment mean in response to familiarity with HFI was 1.6; the post
assessment familiarity average response was 3.06; follow-up assessment mean response was 3.
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Table 2
Changes in Reported Familiarity with Hereditary Fructose Intolerance
Preassessment

Post-assessment

Choice (%)

Choice (%)

Follow-up
Assessment
Choice (%)

No, not at all

30 (66.7%)

3 (10%)

0 (0%)

I am not sure

9 (20%)

1 (3.3%)

1 (16.7%)

6 (13.3%)

21 (70%)

4 (66.7%)

0 (0%)

5 (16.7%)

1 (16.7%)

45 (100%)

30 (100%)

6 (100%)

Yes, somewhat familiar
Yes, very familiar
Total

In a similar manner to the question about HFI, participants were asked about their
familiarity with FM. While participants were not directly educated about FM in the learning
module, FM was discussed in relation to HFI. Table 3 illustrates the reported familiarity with
FM. Responses are also reported as percentages to account for the variation in sample size. By
ranking the answer choices based on their ordinal level (1=No, not at all; 2= I am not sure; 3=
Yes, somewhat familiar; 4= Yes, very familiar) the mean response of all participants was
calculated. The preassessment mean in response to familiarity with FM was 1.56; the post
assessment familiarity average response was 2.8; follow-up assessment mean response was 3.
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Table 3
Changes in Reported Familiarity with Fructose Malabsorption
Preassessment

Post-assessment

Choice
(Percentage)

Choice (Percentage)

No, not at all

29 (64.4%)

5 (16.7%)

0 (0%)

I am not sure

7 (15.6%)

0 (0%)

1 (16.7%)

Yes, somewhat familiar

9 (20%)

21 (70%)

4 (66.7%)

Yes, very familiar

0 (0%)

4 (13.3%)

1 (16.7%)

45 (100%)

30 (100%)

6 (100%)

Total

Follow-up
Assessment
Choice
(Percentage)

Symptoms Associated with HFI. Participants were asked to select symptoms they
believed were associated with a patient presenting with HFI. Participants were asked to choose
as many options as they felt appropriate from four choices; nausea and vomiting, postprandial
hypoglycemia, distaste for sweets, and failure to thrive. Reporting of frequency and the mean
number of options each participant selected is presented in Table 4. Also shown is the percentage
of participants who chose this choice due to the discrepancy in participation between the
sections.
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Table 4
Presentation of Symptoms in HFI
Preassessment
(n=45)
N (%)

Postassessment
(n=30)
N (%)

Follow-up
Assessment
(n=6)
N (%)

Nausea and Vomiting

25 (55.5%)

28 (96.7%)

6 (100%)

Postprandial Hypoglycemia

22 (48.9%)

28 (96.7%)

6 (100%)

Distaste for Sweet Tastes

17 (37.8%)

22 (76.7%)

4 (66.7%)

Failure to Thrive

24 (53.3%)

30 (100%)

5 (83.3%)

1.95

3.76

3.5

Mean

Choice of Diagnostic Test. Participants were presented with six options for diagnostic
tests for a patient presenting symptoms of HFI. Participants were asked to select the choices they
would want to order if they were the clinician. The options provided included genetic testing, the
safest and most productive diagnostic test, and liver biopsy, which could diagnose HFI but has
significant risks associated with the procedure. Unsafe diagnostic procedures included the
Intravenous Fructose Challenge and the Hydrogen Breath Test. Other options were not
dangerous, but they would not yield a diagnosis of HFI. Table 5 displays the frequency and
percentage of participants who selected each option during each portion of the project.
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Table 5
Choice of Diagnostic Test
Preassessment
(n=45)
16 (35.6%)

Postassessment
(n=30)
5 (16.7%)

Follow-up
Assessment
(n=6)
1 (16.7%)

Liver Biopsy

3 (6.7%)

6 (20%)

0 (0%)

Endoscopy

1(2.2%)

1 (3.3%)

0 (0%)

Genetic Testing

14 (31.1%)

27 (90%)

6 (100%)

IV Fructose Challenge

11 (24.4%)

7 (23.3%)

2 (33.3%)

Hemoglobin A1C

23 (51.1%)

7 (23.3%)

5 (83.3%)

Hydrogen Breath Test
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Chapter 5: Discussion of Project Findings and Implications
Data analysis included examination of the pre- and post-assessment items given during
the module. This information was then discussed in terms of alignment with the current,
available literature on HFI.
Data collected from the three assessments attempted to determine if participants would
report a change in their self-report of familiarity with HFI at three different points. Based on the
results, there was an increase in participants who reported being somewhat familiar (13.3% to
70%) and very familiar (0% to 16.7%) after completing the assessment. There was also a
decrease in participants who reported that they were not familiar (66.7% to 10%). Based on the
significant difference in sample size and attrition at the 1-month follow-up evaluation, it was
difficult to determine whether this change was substantial. However, the purpose of this project
was to increase awareness of HFI. Based on these results, this overall global aim was met.
Symptom Identification
In Table 4, the participant selections for symptoms associated with HFI. In alignment
with the goals of this project, participants identified more symptoms during the preassessment
(the mean of symptoms selected was 1.95 in the preassessment to 3.76 in the post-assessment).
Although representing only a portion of the original participants, the follow-up assessment still
had a mean of 3.5 symptoms selected, which they believed were associated with HFI.
Choice of Diagnostic Test
Along with the identification of HFI in patients, the choice of the diagnostic test must be
safe and sensitive in the ability to confirm the diagnosis. Participants selected the diagnostic tests
that they would order for the presenting patient. As predicted, implementation of the learning
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module led to a decrease in the choice of unsafe diagnostic tests (Hydrogen Breath Test and IV
Fructose Challenge).
Also of note is the increase in the frequency and percentage of participants who chose
genetic testing to diagnose HFI. As seen in Table 6, 31.1% of participants initially chose this
option, and 90% of participants selected this option in the post-assessment. There was also an
increase in participants who selected liver biopsy as a diagnostic test from the preassessment
(6.7%) to the post-assessment (20%).
Table 6
Appropriateness of Choice of Diagnostic Test
Diagnostic
Test
Unsafe
Diagnostic Tests
Inappropriate
Choice of Tests
Appropriate
Diagnostic Test
Best Choice of
Diagnostic Test

(n=45)
16 (35.6%)

Postassessment
(n=30)
5 (16.7%)

Follow-up
Assessment
(n=6)
1 (16.7%)

11 (24.4%)

7 (23.3%)

2 (33.3%)

1 (2.2%)

1 (3.3%)

0 (0%)

Hemoglobin
A1C
Liver Biopsy

23 (51.1%)

7 (23.3%)

5 (83.3%)

3 (6.7%)

6 (20%)

0 (0%)

Genetic
Testing

14 (31.1%)

27 (90%)

6 (100%)

Hydrogen
Breath Test
IV Fructose
Challenge
Endoscopy

Preassessment

Discussion
The findings from this project were consistent with the hypothesized lack of awareness of
HFI. This hypothesis is consistent with the discussions in research regarding HFI being more
prevalent than what is seen due to mutations still being unidentified (Ali & Cox, 1995; Ali et al.,
1998; Ali et al., 1994; Brooks & Tolan, 1993; Gaughan et al., 2015).
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While research does not specifically address the lack of awareness or need for more
education about HFI, the research supports a danger in the increased amounts of sugars in food
and beverages resulting in a need for increased vigilance and awareness of HFI (Akram &
Hamid, 2012; Ali et al., 1998; Cox, 1991; Li et al., 2018).
The findings from this project show an increased average in the self-reported awareness
in HFI from preassessment to post assessment (1.6 to 3.6) and preassessment to follow-up
assessment (1.6 to 3) where 1 indicates no, not at all and four indicates yes, very familiar.
Findings for FM familiarity from preassessment to post assessment (1.56 to 2.8) and
preassessment to follow-up assessment (1.56 to 3) were not as drastic which was expected as FM
was only discussed in contrast to HFI and not in depth in this module.
Regarding choice of symptoms related to HFI, there was an increase in the number of
symptoms selected from preassessment to post assessment (1.95 to 3.76) and from preassessment
to follow-up assessment (1.95 to 3.5). This indicated that the increased knowledge of symptoms
associated with HFI from the baseline.
Similar results indicated an increased awareness of selection of diagnostic test from
preassessment to post assessment and preassessment to follow-up assessment. Approximately
31% of participants selected genetic testing as a diagnostic test during the preassessment. This
number increased to 90% and 100% (n=6) of participants in the post assessment and follow-up
assessment. In contrast, 35.6% (n=16) of participants selected hydrogen breath test and 16.7%
chose this option in both the post module (n=5) and follow-up assessments (n=1).
Contrary to the desired increase in awareness was the results surrounding the selection of
intravenous fructose challenge. On the preassessment, 24.4% (n=11) of participants selected this
choice followed by 23.3% (n=7) on the post assessment and 33.3% (n=2) on the follow up.
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These findings, including the lack of change in the selection of intravenous fructose
challenge is consistent with the findings in literature regarding the significant dangers for those
with HFI undergoing medical treatments (Ali & Cox, 1995; Ali et al., 1998; Cox, 1993; Cox,
1995; Gaughan et al., 2015; Li et al., 2018).
Overall, of the three key aims discussed previously, these results supported an increased
awareness of HFI and FM in this project, indicating these aims were met. The second aim of
increasing knowledge of the appropriate diagnostic test in potential HFI patients can be seen in
the increased selection of genetic testing by participants discussed previously. Lastly, as many
participants were SHU students, the results of this project overall supported the increased
awareness regarding symptom of HFI, and choice of diagnostic test indicated that this project
was effective in increasing awareness within this population.
Strengths and Limitations of the Project
This project had may strengths and limitations which likely impacted the outcomes. As
far as strengths of this project, the biggest strength was the virtual platform used for completion
and sustainability of the project. This strength in design allowed for ease of use by participants
and the flexibility for completion. As the project progressed, this virtual platform allowed for a
continuation of this project due to the COVID-19 pandemic occurring during the implementation
phase of this project.
The DNP student had immediate access to the APRN student population since she was
an enrolled DNP student at Sacred Heart University. Since this project was developed for use
within an APRN student population, this module fit nicely with this targeted population and
setting. Further, the project was meant to assess basic knowledge and increase awareness of HFI
to allow current and future practitioners to identify the differentials surrounding HFI. Therefore,
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the information in this module was purposely intended to include basics information around
specific symptom patterns indicative of HFI as well as appropriate, and safe diagnostic tests.
This information was easy to read and easily accessible to students and a strength in the project
design.
Limitations surrounding this project including the timing around implementation.
COVID-19 occurred between the creation and planning of this project and was a worldwide
pandemic during the project implementation phase. The original project plan including
interaction with practicing healthcare providers and the COVID-19 environment did not allow
for a safe, effective space for the original project plan to be conducted. Further, healthcare
providers were faced with unprecedented stressors which did not allow for time to introduce a
knowledge-based DNP scholarly project in the field. These limitations led to a shift in project
design to focus on the targeted student population who were preparing to be future APRN
providers. Despite this shift, significant attrition from the preassessment (n=45) to postassessment (n=30) to the 1-month follow-up (n=6) was found.
Another potential recognized limitation to this project was a potential participant biases
in the student population who participated. This DNP student was the author and presenter of
many DNP assignments which also focused on HFI which could have given students baseline
knowledge and recognition of some of the materials.
Project Implication for the Field
The results found in this project illustrated a gap in the education of a nurse practitioner
and physician assistant programs regarding HFI and other inborn errors of metabolism. It also
shows that a learning module with basic information about this diagnosis was sufficient in
increasing knowledge in some current and future practitioners allowing for safer diagnosis and
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initiation of care for these patients. Overall, increasing awareness of HFI will allow for progress
toward closing the knowledge gap in healthcare providers. This will ultimately help clinicians in
the diagnosis of current and future patients with HFI to allow for safer diagnosis and timelier
introduction of safe interventions. Further, identification of the symptoms of HFI, knowledge of
the safest diagnostic testing methodologies, awareness of the severity of lack of or inappropriate
treatment may potentially increase awareness of the possibility that metabolic disorders other
than HFI can cause.
Key Lessons Learned
During the implementation of this project, it became clear that inborn errors of
metabolism are not covered in the current APRN curriculum at the College of Nursing at Sacred
Heart University. Based on the similarity in the responses to self-reported familiarity with HFI
and FM, there is likely a gap in education in other educational programs for APRNs and PAs. In
conjunction with this finding, the discrepancy in the number of responses between students and
clinicians showed that introducing this information would make the most significant impact
when introduced within an educational setting.
Sustainability Plan
To ensure that the findings of this project are responded to appropriately, the continued
use of the learning module and possibly the assessments will be presented to the faculty of
SHU’s APRN and PA programs. The sustainment of this project, whether as a learning module, a
continuing education module, or an introduction to course material, would ideally lead to success
in increasing Sacred Heart University student knowledge base of HFI. This project virtual
platform (website) will remain active and up to date with the most recent evidence related to HFI
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by a subject matter expert, currently a certified family nurse practitioner student in Connecticut
and soon to be licensed upon graduation.
Summary
In HFI and many other metabolic disorders, early diagnosis and dietary intervention can
often spare a patient from any possible illness, organ damage, and unnecessary suffering by
strictly adhering to a diet free of fructose, sucrose, sorbitol, and other precursors of fructose.
Timely diagnosis and intervention are key to avoid unnecessary medical costs and the diagnostic
testing many patients often undergo before diagnosis. Increased awareness and understanding in
clinicians will result in the best possible outcomes for patients with HFI.
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Chapter 6: Dissemination and Sustainability
Dissemination
An overview of this student project as well as the use and availability of this module will
be written and submitted to a nurse-led journal such as “Nurse Education Today.” Further, the
website created for this project will be maintained for use by future students, clinicians, and the
public as a professional, scholarship of this DNP student. Overall, the research related to HFI is
lacking comprehensive guidelines for patients and providers and clinical guidelines are needed
for the field. Potential submission of this material in the form of an integrative literature review
or critical analysis of available literature will be considered in the future.
The results of this project will be disseminated in a poster presentation as a course
requirement at Sacred Heart University in NU 820. The poster or abstract of this project will also
be submitted to local conference, identified in the future. Additionally, this project overview will
be submitted as a course requirement for NU 824 as well as uploaded to the DNP Repository
online as a requirement for the Doctorate in Nursing Practice degree at Sacred Heart University,
College of Nursing.
Sustainment
The future use of these project materials would be beneficial to students and clinicians
alike. This DNP student will maintain the upkeep of this HFI virtual information platform as part
of her own APRN scholarship.
It was found that the Family Nurse Practitioner curriculum at Sacred Heart University
was limited in the discussions regarding genetic diseases with nearly no discussion of inborn
errors of metabolism, such as HFI. While this is similar to that found on review and critical
appraisal of available literature in the field, continued advancement requires recognition of
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illness and disease that new and emerging APRNs need to know to safely practice in the
community. Based on the experiences gained from this project, future use of this module would
be more effective if incorporated into formal course curriculum such as SHU’s APRN programs.
Sustainability of this project relies on further dissemination of these project materials in
order to decrease the frequency of which HFI and other inborn errors of metabolism occur and
go undiagnosed. Early identification of HFI leads to complication-free development and a future
free from severe morbidity and mortality. Knowledge of HFI remains imperative and should be
priority for incorporation into APRN curriculum and continuing education modules for current
practicing practitioners.
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Appendix A

Comparison of Hereditary Fructose Intolerance and Fructose Malabsorption

Pathophysiology

Hereditary Fructose Intolerance

Fructose Malabsorption

Autosomal recessive metabolic
disorder in which individuals do
not produce or produce
ineffective Aldolase B. This
enzyme is necessary for the
metabolism of fructose, sucrose,
sorbitol, and their precursors.
Ingestion of these substances
results in an accumulation of
hepatic Fructose-1-Phosphate,
which interferes with normal
cellular function.

Metabolism of nutrients is
impaired due to the problem of
membrane transport systems in
the epithelium of the small
intestine. Individuals can be born
with it (primary malabsorption),
or it can be developed (acquired
malabsorption)

Upon introduction to food or
beverages with sugars or
ingredients which metabolize
into fructose. (Complications in
infancy often occur due to sugars
in infant formula)
Hepatic damage (hepatomegaly,
jaundice, fatty liver), hepatorenal
failure, seizures, coma, and
death.
Aversion to sweet tastes,
otherwise asymptomatic if all
sugars that metabolize into
fructose are avoided.

Varies

Prevalence
Age at time of presentation

Possible complications

Symptoms

Malabsorption, diarrhea, weight
loss

Bloating, abdominal pain,
nausea, heartburn, gas, and
diarrhea

Acute intoxication with fructose
or other sugars: nausea,
vomiting, abdominal pain, postprandial hypoglycemia
Long-term exposure: failure to
thrive, hepatic damage,
hepatorenal failure, seizures,
coma, and death.
The goal of treatment/ dietary
modification

Implement dietary interventions
and live a symptom-free life

Avoid symptoms associated with
ingestion of fructose
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Dietary intervention

Complete avoidance of food and
beverages containing fructose,
sucrose, sorbitol, and their
precursors

Avoid foods with more fructose
than glucose, items sweetened
with fructose (including
crystalline fructose or high
fructose corn syrup or honey).
Temporarily avoid fruits with
high fructose concentration
(apples, pears, prunes, dates).
Reintroduce them if symptoms
are not significantly better with
exclusion.
Limit beverages with high
fructose corn syrup to 12 ounces
per day. Minimal caffeine
intake; avoid sorbitol and sugar
alcohols.

Diagnosis

Genetic testing

Fructose Breath Test

American Gastroenterological Association, 2020; Mason, 2019
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Appendix B

Data Organization Chart
Article
Information

Diagnosis

(See
reference
list below)
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Appendix C

Evidence Table for PICO Question
EBP Question: Will introducing a teaching tool of best practices for Hereditary Fructose Intolerance lead
to increased awareness among health care providers?
Article
abbreviate
d title

Author
& Year

Evidenc
e Type

Sample,
Sample
Size,
Setting

Findings that help
answer clinical
questions/ Notes

Limitations

Nonalcoholic
fatty liver
in
hereditary
fructose
intolerance

Aldámi
zEchecar
ria et
al.,
2018

Crosssectional,
observati
onal

16
genetica
lly
diagnos
ed
patients
between
3 and
48 on
an HFI
diet for
at least
two
years

Assessing the
prevalence of
nonalcoholic fatty
liver in HFI patients
Great description of
the importance of
Aldolase B.
Looks at the
correlation between
specific mutations and
the likelihood to have
NAFLD (7 of 9 with
Ala150, 3 of those had
hepatomegaly
compared to 2 of 6
with
c.360_363delCAAA0 had hepatomegaly

Inclusion criteria
include dietary
compliance- what
diet are they
following, what
maximum daily
amount of
harmful sugars?
How do they
measure this?
Nutritional status
based only on
BMI
Patients had
different genetic
mutations.

The frequency of HFI
is not precise, and
recognition is vital

The article’s focus
is to increase
genetic screening

Diverse
mutations
in the

Ali &
Cox,
1995

Letter to
the editor

Depart
ment of
Medicin

Vague dietary
recommendations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up
Begin with
an
introduction
to foods
Sxs: FTT,
vomiting
and pain,
jaundice,
liver failure.
Metabolism
alterationshypoglycem
ia, metabolic
acidosis,
hypophosph
atemia,
hyperuricem
ia,
hypermagne
semia,
hyperalanine
mia,
elevated
serum
carbohydrate
-deficient
transferrin
Late dx
without
dietary
interventionrenal and
hepatic
seizures,
coma, or
death

Evidence
Rating†
Level/Qualit
y

III

B/C

V

A
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Article
abbreviate
d title

Author
& Year

Evidenc
e Type

aldolase B
gene
underlie
the
prevalence
of
hereditary
fructose
intolerance.
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Sample,
Sample
Size,
Setting

Findings that help
answer clinical
questions/ Notes

Limitations

e. U. of
Cambri
dge.
Addenb
rooke’s
Hospital

since it responds well
to the dietary
exclusion of fructose,
sucrose, and sorbitol.
Evidence that there are
more mutant alleles of
aldolase B than
initially thought
because

to determine the
actual frequency
of HFI.

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up

Evidence
Rating†
Level/Qualit
y

Nonconsanguineous
parents have had more
kids with HFI
After making it
through infancy, more
people may identify
with having HFI

Hereditary
fructose
intolerance

Ali,
Rellos
et al.,
1998

Opinion
of
nationall
y
recogniz
ed
experts

Depart
ment of
Medicin
e. U. of
Cambri
dge.
Addenb

Administration of
fructose-based
solutions has resulted
in at least 16 deaths of
patients who
unknowingly had HFI
Some reports of a
large amount of HFI
within extended,
nonconsanguineous
families suggest the
disease alleles are
prevalent in the USA
in European
populations.
Emphasis on the
dangers of IV sugars
during things such as
minor procedures and
the severity (risk of
death)
The function of
aldolase B “catalyzes
the specific and
reversible cleavage of
the glycolytic hexose
substrates, fructose 1phosphate, into 3carbon sugars,

Article from 1998

V

A
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Article
abbreviate
d title

Author
& Year

Evidenc
e Type
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Sample,
Sample
Size,
Setting

Findings that help
answer clinical
questions/ Notes

rooke’s
Hospital

dihydroxyacetone
phosphate, Dglyceraldehyde 3phosphate, and Dglyceraldehyde.
Aldolase B is found in
the liver, kidneys, and
small intestine.
Aldolase B is under
dietary control and is
inactive under resting
conditions.
Infants are most
vulnerable when
weaning from
breastmilk- sxs when
given
formula/fruit/vegetabl
es
Vomiting
Nausea
Hypoglycemia
Metabolic acidosis
Lg quantities- more
severe reactions,
lethargy, seizures, and
coma
Persistent intakesyndrome of chronic
toxicity, irreversible
damage to liver and
kidney, cirrhosis, and
death
The mother/caretaker
plays a critical role in
nutrition and keeping
the patient safe. Must
be cautious of
interference from
other family members
(grandparents giving
honey)
Self-protective
aversion to food that
causes distress is
refined through trial
and error.

Limitations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up

Evidence
Rating†
Level/Qualit
y
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d title

Author
& Year

Evidenc
e Type

Sample,
Sample
Size,
Setting
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Findings that help
answer clinical
questions/ Notes

Hazard uses fructose
infusions for
parenteral feedings
(20+ fatal cases)fructose IVs are no
longer used- glucose is
better for people with
diabetes (who fructose
was thought to be
better for). It is
destructive for HFI
and toxic for everyone
else.
Treatment- strict
exclusion diet with an
experienced dieticiannormal health and
development return
quickly if tissue
damage is not too
severe.
Caution using meds
and syrup (sucrose and
sorbitol are used often)
Pts should take
supplements of watersoluble vitamins, folic
acid, and vitamin c.
Medic alert bracelet
with prohibited sugars
and appropriate
treatment for
hypoglycemia
(glucose and milk for
parenteral and oral
use.
In HFI, incorporation
of fructose to glycogen
was less than 6%suggests that the
fructose is primarily
catalyzed by Aldolase
B and that alternative
pathways for direct
conversion of fructose
1-phosphate to
fructose-1,6

Limitations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up

Evidence
Rating†
Level/Qualit
y
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Article
abbreviate
d title

Null alleles
of the
aldolase B
gene in
patients
with
hereditary
fructose
intolerance

Author
& Year

Ali,
Tuncma
n, et al.,
1994

Evidenc
e Type

Case
Report

Sample,
Sample
Size,
Setting

Four
sympto
matic
patients
in
Souther
n
Turkey

69
Findings that help
answer clinical
questions/ Notes

biphosphate in human
liver tissue are limited.
Rare mutant alleles of
aldolase B can be
overlooked and fail to
diagnose the condition
by this means.

Limitations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up

Evidence
Rating†
Level/Qualit
y

1 in 20,000
Sxs:
hypoglycem
ia,
hypophosph
atasemia,
and acidosis.
Continued
exposure
leads to
growth
retardation,
hepatic
injury, and
eventually
death.
DX:
intravenous
fructose
tolerance
test but this
procedure,
and others
based on
enzymatic
assay of
tissue biopsy
samples
(liver
biopsy) or
31P
magnetic
resonance
spectroscop
y, five are
too
cumbersome
or invasive
for general
use in the
population.
Recommend
s genetic
testing

V

A
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Article
abbreviate
d title

Author
& Year

Evidenc
e Type

Sample,
Sample
Size,
Setting

Association
of the
Widesprea
d A149P
hereditary
fructose
intolerance
mutation
with newly
identified
sequence
polymorphi
sms in the
aldolase B
gene

Brooks
&
Tolan,
1993

Assessin
g DNA
for new
mutation
s

DNA
sequenc
ing on
32
blood
samples

An
independen
t diagnosis

Cox,
1990

Fructose
intolerance:
diet and
inheritance

Cox,
1991

Hereditary
fructose
intolerance

Cox,
1990

Iatrogenic
deaths in
hereditary
fructose
intolerance

Cox,
1993
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Findings that help
answer clinical
questions/ Notes

Limitations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up
Sxs- severe
pain,
vomiting,
hypoglycem
ia
Chronic
intakekidney
damage,
growth
retardation,
coma, death

Evidence
Rating†
Level/Qualit
y

V

B

IV fructose
loading and
measuring
Aldolase B
activity with
liver biopsy
are
dangerous
for pt.
Opinion
of the
nationall
y
recogniz
ed expert
Opinion
of
nationall
y
recogniz
ed
experts
Opinion
of
nationall
y
recogniz
ed
experts
Opinion
of
nationall
y
recogniz

V

V

Fatal cases continue to
occur.
Sucrose and fructose
in infant formula
Before diagnosis,
adults with HFI only

Sxs:
vomiting,
symptomatic
hypoglycem
ia, FTT
during

V

A

V

B
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abbreviate
d title

Author
& Year

Evidenc
e Type

ed
experts

Sample,
Sample
Size,
Setting
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Findings that help
answer clinical
questions/ Notes

ingest a few grams of
fructose or sucrose a
day (a fraction of what
normal adults do), and
cavities are rare, but
they still have
abdominal Sxs and
intermittent
hypoglycemia (due to
accidental dietary
ingestions)
In the absence of
fructose – pts have no
Sxs. Ut exposure to
small amounts of
sugar induces
functional impairment
(i.e., renal tubular
acidosis and
eventually structural
injury in the tissue
sites for metabolism.
Intracellular
sequestration of
fructose-1-phosphate
depletes the
intracellular pool of
free inorganic
phosphate (seen in P
magnetic resonance
spectroscopy in vivo),
which inhibits
glycogenolysis and
gluconeogenesis,
leading to refractory
hypoglycemia.
Feedback inhibition of
ketohexokindase
reduces further
metabolism of fructose
so that when the renal
threshold is exceeded,
this reducing sugar is
in the urine.
Parenteral
administration of

Limitations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up
weaning or
transfer
from breast
milk to fruit
juice or
artificially
sweetened
foods- infant
has episodes
of disturbed
consciousne
ss,
hypoglycem
ia seizures.
Chronic
ingestionjaundice,
liver
enlargement,
renal tubular
dysfunction,
hemorrhagic
tendency,
hepatic
failure,
possible
death.
Growth
retardation
accompanie
d by
biochemical
abnormalitie
s occur
unless
dietary
fructose is
reduced to
less than 40
mg/kg/day.
DX- IV FTT
and Liver
biopsy used
to be done.
Now PCR
based

Evidence
Rating†
Level/Qualit
y
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Article
abbreviate
d title

Author
& Year

Evidenc
e Type

Sample,
Sample
Size,
Setting
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Findings that help
answer clinical
questions/ Notes

Limitations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up
methods of
DNA
analysis are
well
established.

Evidence
Rating†
Level/Qualit
y

Management
recommendations
are very vague.
Inaccurate dietary
guidelines

Medic alert
bracelets
Has dietary
guidelines
(not
accurate)
Caution with
formula,
medication,
nutritional
drinks,
enemas, etc.,
parenteral
medications

IV

fructose and invert
sugar or sorbitol is
rapidly converted to
fructose by sorbitol
dehydrogenase in the
liver leading to acute
liver cell necrosis and
profound metabolic
acidosis
15 cases resulted in
irreversible
hepatorenal failure-use
of these fluids has
decreased but still
done in Germanspeaking countries
when an article
published

Hereditary
Fructose
Intolerance

Gaugha
n et al.,
2015

Clinical
Practice
Guidelin
es

N/A

Phenylketonuria
occurs with similar
frequency and
responds entirely to
appropriate dietary
treatment. Population
screening before
weaning may be
justified as the most
common mutations
can be easily detected
with PCR methods.
Pilot studies have been
successful using
Guthrie blood stops.
Reviews clinical
characteristics,
diagnostics, and
testing, management,
suggestive findings,
differential diagnoses,
treatment of acute
episodes
No formal guidelines
regarding surveillance
Discussed the use of
sweet ease in neonates
Avoid Hydrogen
breath tests and

B
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abbreviate
d title

Author
& Year

Evidenc
e Type

Sample,
Sample
Size,
Setting
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Findings that help
answer clinical
questions/ Notes

Limitations

fructose tolerance
testing.
Very little evidence
about HFI in
pregnancy.
Consider banking the
DNA of affected
individuals for future
research

Neonatal
screening
for
hereditary
fructose
intolerance:
frequency
of the most
common
mutant
aldolase B
allele
(A149P) in
the British
population
An
empirical
estimate of
carrier
frequencies
for 400+
causal
Mendelian
variants:
results
from an
ethnically
diverse
clinical
sample of
23,453
individuals

James et
al.,
1996

Systemat
ic review

A
random
cohort
of 2050
subjects
born in
1994
and
1995

Lazarin
et al.,
2013

Nonexpe
rimental
study

Twentythree
thousan
d four
hundred
fiftythree
individu
alsresults
from
genetic
testing.
Ethnical
ly
diverse

PCR was used to
amplify the AdolB
gene in Guthrie card
blood spots.
1.32 +/1 0.49% (95%
confidence interval) of
samples were
heterozygous for HFI.
The estimated
prevalence of 1 in
23,000
Findings have
implications for
inclusion in newborn
screening
Looks at the
prevalence of carriers
of AldoB mutation
associated with HFI in
a large population and
the genetic majority of
HFI compared to
genetic prevalence in
the literature.
Caucasians, 1 in 90.1
in the study but 1 in
81.1 in literature.
African Americans 1
in 226, but no
literature to compare
to

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up
should be
cleared by
the
pharmacist
and team on
a case by
case basis.
Use of
vitaminswhich ones?
Use medic
alert- what
info is the
MD going to
find?

Evidence
Rating†
Level/Qualit
y

Prevalence is
different in
different
countries, as are
mutations.

I

A

75% female.
Research to
compare findings
is not done.

III

A

Most Americans
in the study and
genetic mutations
are different in
different
countries.
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abbreviate
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Author
& Year

Evidenc
e Type

Sample,
Sample
Size,
Setting
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Findings that help
answer clinical
questions/ Notes

Limitations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up

Evidence
Rating†
Level/Qualit
y

Middle Eastern 1 in
97, but no literature to
compare to
Chronic
Fructose
Intoxicatio
n After
Infancy in
Children
with
Hereditary
Fructose
Intolerance
: A Cause
of Growth
Retardation
Newborn
Screening
for
inherited
metabolic
disorders;
news and
views

Mock,
Perman,
Thaler
&
Morris,
1983

Pourfar
zam, &
Zadhou
sh, 2013

Decreasing dietary
fructose increased the
growth rate in
children. Patients’ diet
was already low
enough to prevent
symptoms, but they
instituted more
stringent guidelines
(appx 40 mg/kg/day)

Guidelin
es on
newborn
screening

n/a

Newborn screening is
used to identify
genetic metabolic
disorders in apparently
healthy infants. These
are usually corrected
by diet or medications.
Newborn screening
allows for the early
detection of many
disorders.
Each disorder is
individually rare, but
their cumulative
incidence is relatively
high, around 1 in 1500
to 1 in 5000 live
births.
WHO Wilson–Jungner
criteria, a disease that
has the following
properties should be
screened:
(1) a vital health
problem; (2) the
natural history of the
condition should be
adequately
understood; (3) it

IV

No specific HFI
information

A
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Author
& Year

Evidenc
e Type

Sample,
Sample
Size,
Setting
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Findings that help
answer clinical
questions/ Notes

should be recognizable
in the early stages; (4)
there should be a
suitable test or
examination; (5) the
test should be
acceptable to the
population; (6)
intervals for repeating
the test should be
determined; (7) there
should be an accepted
treatment for patients;
(8) facilities for
diagnosis and
treatment should be
available; (9) there
should be an agreed
policy concerning
whom to treat as
patients; and (10) the
costs of case finding
should be
economically balanced
against the benefits

†Use John Hopkins Evidence Level and Quality Guide

Limitations

Factors
Discussed
S/SX; DX;
treatment;
follow up
recommend
ations for
follow-up

Evidence
Rating†
Level/Qualit
y
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Appendix D

Evidence Synthesis Table
Article Number

1

2

3

4

5

6

7

8

9

10 11 12 13 14

Level 1: Systematic review
or meta-analysis
Level II: Randomized
Control Trial
Level III: Controlled Trial
without Randomization
Level IV: Case-control or
cohort study

X
X

X

X

Level V: Systematic
Review of quality and
descriptive studies
Level VI: Qualitative or
descriptive study, CPG,
Lit Review, QI, or EBP
project

X

Level VII: Expert opinion

Article Number

X

15

16

X

X

17

18

X

X

X

19

20

21

22

X

X

23 24

X

25

TOTAL

Level 1: Systematic
review or meta-analysis

0

Level II: Randomized
Control Trial

0

Level III: Controlled
Trial without
Randomization

1

Level IV: Case-control or
cohort study

X

X

X

6
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Level V: Systematic
Review of quality and
descriptive studies
Level VI: Qualitative or
descriptive study, CPG,
Lit Review, QI, or EBP
project
Level VII: Expert opinion

0

X

X

X

X

X

X

X

X

9

9
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Appendix E

Rationale for Answer Options

Akram, &
Hamid, (2013)
AldámizEchevarría et al.,
(2019)
Ali, & Cox,
(1995)
Ali, Rellos, &
Cox, (1998)
Ali, Rosien &
Cox, (1992)
Ali, Tuncman, et
al.,1994
Brooks & Tolan,
1993
Cox, 1991
Cox, 1990a
Cox, 1990b
Cox, 1993
Cross & Cox,
1990
Gaughan et al.,
2015
James et al., 1996
Kim et al., 2020
Kim et al., 2021
Li et al., 2018
Mock et al., 1983
Steinmann & van
den Berghe, 2006

Patient Presentation
N/V
PP
Distaste
Hypo
for
Sweet
Tastes
X
X
X

X

X

X

X

FTT

Diagnostic Test
Genetic Liver
Testing Biopsy

IV FC

ND

ND

X

X

X

X

-

X

X

X

X

X

X

X

X

X

X

X

X

X

X
X
X
X
X

ND

HBT/
Avoid
dietary
sugar
X
X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X
X
X
X
X

X
X
X
X
X

X
X
X
X

X
X
X
X

X
X

O
O
X
O

X
X
X
X
X

X

X

X

X

X

X

X

X

X
X
X
X
X
X

X
X
X
X
X
X

X
X
X
X
X
X

X
X
X
X
X
X

X
X
X
X

X

X

X

X

X

X

O
X

X
X
X
X
X
X
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Appendix F

Screenshot of Homepage
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Appendix G

Contents of Website
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Appendix H

Iowa Model for Evidence-Based Practice

(uihc.org, 2020)
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Appendix I

Introductory Letter for Providers

Dear Dr., APRN, or PA,
My name is Jacqueline Bridge. I am a Doctorate of Nursing Practice (DNP), Family Nurse
Practitioner (FNP) student at Sacred Heart University, College of Nursing. I am currently
recruiting primary care medical providers in Connecticut who specifically care for pediatric
patients to participate in an evidence-based learning module for my DNP doctoral project.
My project focuses on Hereditary Fructose Intolerance (HFI), an autosomal recessive metabolic
disorder, which is not readily included in pediatric medicine or nursing educational programs
and often missed on diagnosis: which delays treatment and, in some cases, can be fatal. My
personal experience with HFI includes being misdiagnosed as a child resulting in severe liver
and organ compromise. I was diagnosed with failure to thrive after being weaned from
breastmilk and introduced to fruit. After more than three years of searching for help, I was
eventually diagnosed. However, other patients are often not so lucky.
The aim of this project is to increase awareness of HFI as an often-misdiagnosed metabolic
disorder and highlight the clinical symptoms in which patients may present. The global aim is to
create awareness in practicing pediatric clinical care providers in order to avoid unnecessary
illness and suffering of patients and their families, where diagnosis is often delayed or missed
altogether.
This activity includes a provider pre-survey, a brief learning module estimated to take 20
minutes, and then a post-survey. I will reach out to you in three months after the initial
learning module for follow-up questions. This learning module is available 100% online.
I will be launching this project in August-September of 2020. The purpose of this email is to
identify clinics and primary care providers willing to participate in this project. If you are willing
to participate, can you please respond in this email and include how many providers at your
practice are willing to participate?
If you have any questions or concerns, please feel free to reach me at
Mahonyj@mail.sacredheart.edu or on my cell phone at 203-331-6004.
Thank you for your time and consideration,

Jacqueline Mahony Bridge, RN
Anna Goddard, PhD, APRN (Faculty Advisor)

5151 Park Avenue, Fairfield, Connecticut 06825-1000 | www.sacredheart.edu
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Appendix J

Introductory Letter for Sacred Heart Department Directors
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Appendix K
Preassessment
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Appendix L

Post Module Assessment
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Appendix M

Follow Up Assessment
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Appendix N

Differentiating Quality Improvement and Research Activities
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Appendix O

Timeline for Implementation
Project Title: Increasing Awareness of Hereditary Fructose Intolerance:
An Evidence-Based Practice Implementation Project
Project Mentor: Dr. Anna Goddard
Doctor of Nursing Practice Project Roadmap
Component

Definition

Date Done

Phase 1: Problem Identification and Evidence Review
Clinical Inquiry
includes the
background and
significance of the
problem
Organizational
priority

Describe the local situation and its importance. Have
data to frame local issues.

1/20

Summarizing information that supports the
topic/problem is an organizational priority.

1/20

Searchable Question

Write a focused, searchable question using an established 1/20
method (e.g., PICO).

Evidence search

External evidence
•

Summarize search strategy (e.g., databases,
keywords, filters/limits, article selection criteria,
critical appraisal tools). Include practice-based
evidence (e.g., evidence-based solutions that
experts/other health systems have implemented to
address practice problems).

Internal evidence
•

n/a

Summarize applicable
unit/community/department/hospital/organization
al level data or data required for national entities
(e.g., CMS, NDNQI, AHRQ).

Perform needs assessment if applicable.
Evidence appraisal,
summary, and
recommendations

1/20

n/a

Organize evidence that answers focused clinical
questions clearly and concisely (e.g., table or matrix).
Appraise literature for quality and applicability of
evidence using an established method (e.g., Johns
Hopkins Nursing EBP Research Evidence Appraisal

1/20-8/20
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Tool, Joanna Briggs Institute Critical Appraisal Tools,
Fuld Institute for EBP critical appraisal tools, etc.).
State recommendations(s) and link to evidence strength,
quality, and risk/benefits.
Phase 2: Project Planning
Project goals

The state intended realistic outcomes of the project using
an established method (e.g., SMART criteria).

4/2-6/20

Framework

Select framework/model to guide implementation (e.g.,
EBP model, QI framework, Change model).

4/20-6/20

Context

Describe the project setting and participants or
population, or other elements central to where the change
will occur.

6/20

Key stakeholders

Identify agencies, departments, units, individuals needed
to complete the project and affected by the project, and
strategies to gain buy-in.

6/20

Practice
change/intervention

Provided detailed description of practice change or
intervention (e.g., new or revised policy).

6/20

Evaluation

Summarize the plan for evaluating the effectiveness of
the practice change. Identify applicable process and
outcomes data to be collected/tracked and tools. Identify
the methods for analyzing/interpreting the data (e.g.,
control, run, or Pareto charts).

6/20

Possible barriers to
implementation

Identify possible barriers and implementation strategies
to mitigate these barriers.

6/20

Sustainment

Identify strategies to sustain the change.

6/20

Timeline

Create a realistic timeline for project completion.

6/20

Resources

Identify all resources (e.g., indirect and direct) needed to
complete the project.

6/20

Ethical merit

Identify and obtain the required review and approval for
implementation (e.g., institution, community agency,
IRB).

6/20

Phase 3: Implementation
Implement project

Carry out the project using the selected implementation
framework/model.

10/2complete
by 2/20/22

Track any deviations/changes from the project plan.

10/21complete
by 2/20/22
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Phase 4: Evaluation
Results/Interpretatio
n

Return on
investment

Using an established method (e.g., run or control charts),
display data and interpret project outcomes.

Currently
collecting
datacomplete
by 2/20/22

Report evaluation of the effectiveness of the practice
change, including the extent to which the practice change
was implemented (process outcome) and the extent to
which the desired product (s) were achieved.

Pending
data
collection
completion
- complete
by 2/20/22

Identify the final resources that were used to implement
the project. Calculate and report the return on
investment.

Pending
data
collection
completion
- complete
by 2/20/22

Phase 5: Dissemination
Traditional

Disseminate the project set in a manner meaningful to
them (i.e., executive report, poster, presentation at a
meeting, sign with QR code to access details of the
project, etc.)

3/22-5/22

Disseminate in the format required by the academic
institution (i.e., poster, public presentation, etc.), and
Prepare final project write-up using established reporting
guidelines (e.g., EPQA, SQUIRE) and educational
institution requirements.
Non-traditional

Develop a website to display projects and use personal or
program social media (e.g., Twitter, Facebook) to share
project information.

1/21current

PICO, Population, Intervention, Comparison, Outcome; CMS, Center for Medicaid and
Medicare Services; NDNQI, National Dataset of Nursing Quality Indicators; AHRQ, Agency
for Healthcare Research and Quality; SMART, specific, measurable, attainable, relevant, timely;
IRB, Institutional Review Board; EPQA, Evidence-Based Practice Process Quality Assessment
Guidelines; SQUIRE, Standards for Quality Improvement Reporting Excellence
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